{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.65","value":"17"},{"groupId":"OG001","spread":"0.71","value":"15.5"},{"groupId":"OG002","spread":"3.51","value":"15.67"},{"groupId":"OG003","spread":"1.96","value":"15.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"Engraftment of Platelets: Platelet engraftment is defined as a platelet count ≥ 20 x 109/L for 3 consecutive measurements obtained on different days. The patient must not have received a platelet infusion for seven consecutive days prior to the first day being considered. The day used as platelet engraftment is the date of the first of three laboratory values.","dispersionType":"Standard Deviation","groups":[{"description":"Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 1: Carfilzomib 15 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6","id":"OG000","title":"Cohort 1: Carfilzomib 15 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 2: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6","id":"OG001","title":"Cohort 2: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 2b: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5","id":"OG002","title":"Cohort 2b: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 3b: Carfilzomib 27 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5","id":"OG003","title":"Cohort 3: Carfilzomib 27mgm2"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.","title":"Platelet Engraftment","type":"SECONDARY","unitOfMeasure":"days"}